{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dobrowolski C"],"funding":["Arthritis Society, Young Investigator Award","Province of Ontario Early Research Award","NCATS NIH HHS","Canadian Rheumatology Association–Arthritis Society Clinician Investigator Award","Department of Medicine, University of Toronto","National Center for Advancing Translational Science","Lupus Research Alliance","National Institutes of Health","Lupus Ontario and Schroeder Arthritis Institute","Arthritis Society of Canada, Canadian Institutes of Health Research, Physician’s Services Incorporated"],"pagination":["1860-1869"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10152298"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["62(5)"],"pubmed_abstract":["Objectives
Cognitive dysfunction (CD) is a common manifestation of SLE that can have detrimental consequences for those affected. To date, no treatments have been approved for SLE-CD. This study aims to assess the association of azathioprine (AZA) and mycophenolate (MMF) use with SLE-CD, given that these medications have demonstrated neuroprotective qualities in prior studies.Methods
Consecutive adult SLE patients presenting to a single healthcare center were considered for participation. The ACR neuropsychological battery for SLE was administered to consenting patients at 0, 6 and 12 months. Scores were compared with age- and sex-matched controls. Primary outcome was CD, defined as a z-score ≤-1.5 in two or more cognitive domains. Mixed-effects logistic regression models w"],"journal":["Rheumatology (Oxford, England)"],"pubmed_title":["Association of mycophenolate and azathioprine use with cognitive function in systemic lupus."],"pmcid":["PMC10152298"],"funding_grant_id":["UL1TR002556","UL1 TR002556"],"pubmed_authors":["Diaz Martinez JP","Wither JE","Katz P","Dobrowolski C","Ruttan L","Choi MY","Su J","Kakvan M","Bingham KS","Touma Z","McGinley J","Beaton DE","Green R","Anderson N","Putterman C","Fazzari M","Bonilla D","Fritzler MJ","Tartaglia MC"],"additional_accession":[]},"is_claimable":false,"name":"Association of mycophenolate and azathioprine use with cognitive function in systemic lupus.","description":"Objectives
Cognitive dysfunction (CD) is a common manifestation of SLE that can have detrimental consequences for those affected. To date, no treatments have been approved for SLE-CD. This study aims to assess the association of azathioprine (AZA) and mycophenolate (MMF) use with SLE-CD, given that these medications have demonstrated neuroprotective qualities in prior studies.Methods
Consecutive adult SLE patients presenting to a single healthcare center were considered for participation. The ACR neuropsychological battery for SLE was administered to consenting patients at 0, 6 and 12 months. Scores were compared with age- and sex-matched controls. Primary outcome was CD, defined as a z-score ≤-1.5 in two or more cognitive domains. Mixed-effects logistic regression models w","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2026-07-14T23:02:14.588Z","creation":"2025-04-06T00:47:21.925Z"},"accession":"S-EPMC10152298","cross_references":{"pubmed":["36135792"],"doi":["10.1093/rheumatology/keac540"]}}